RT Journal Article
SR Electronic
T1 Urine-based multi-omic comparative analysis of COVID-19 and bacterial sepsis-induced ARDS
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.10.22277939
DO 10.1101/2022.08.10.22277939
A1 Batra, Richa
A1 Uni, Rie
A1 Akchurin, Oleh M.
A1 Alvarez-Mulett, Sergio
A1 Gómez-Escobar, Luis G.
A1 Patino, Edwin
A1 Hoffman, Katherine L.
A1 Simmons, Will
A1 Chetnik, Kelsey
A1 Buyukozkan, Mustafa
A1 Benedetti, Elisa
A1 Suhre, Karsten
A1 Schenck, Edward
A1 Cho, Soo Jung
A1 Choi, Augustine M.K.
A1 Schmidt, Frank
A1 Choi, Mary E.
A1 Krumsiek, Jan
YR 2022
UL http://medrxiv.org/content/early/2022/08/10/2022.08.10.22277939.abstract
AB Acute respiratory distress syndrome (ARDS), a life-threatening condition during critical illness, is a common complication of COVID-19. It can originate from various disease etiologies, including severe infections, major injury, or inhalation of irritants. ARDS poses substantial clinical challenges due to a lack of etiology-specific therapies, multisystem involvement, and heterogeneous, poor patient outcomes. A molecular comparison of ARDS groups holds the potential to reveal common and distinct mechanisms underlying ARDS pathogenesis. In this study, we performed a comparative analysis of urine-based metabolomics and proteomics profiles from COVID-19 ARDS patients (n = 42) and bacterial sepsis-induced ARDS patients (n = 17). The comparison of these ARDS etiologies identified 150 metabolites and 70 proteins that were differentially abundant between the two groups. Based on these findings, we interrogated the interplay of cell adhesion/extracellular matrix molecules, inflammation, and mitochondrial dysfunction in ARDS pathogenesis through a multi-omic network approach. Moreover, we identified a proteomic signature associated with mortality in COVID-19 ARDS patients, which contained several proteins that had previously been implicated in clinical manifestations frequently linked with ARDS pathogenesis. In summary, our results provide evidence for significant molecular differences in ARDS patients from different etiologies and a potential synergy of extracellular matrix molecules, inflammation, and mitochondrial dysfunction in ARDS pathogenesis. The proteomic mortality signature should be further investigated in future studies to develop prediction models for COVID-19 patient outcomes.Competing Interest StatementA.M.K.C. is a cofounder and equity stockholder for Proterris, which develops therapeutic uses for carbon monoxide. A.M.K.C. has a use patent on CO. Additionally, A.M.K.C. has a patent in COPD. ES consults for Axle informatics regarding COVID vaccine clinical trials through NIAID. JK holds equity in Chymia LLC and IP in PsyProtix and is cofounder of iollo.Funding StatementJK and RB are supported by the National Institute of Aging of the National Institutes of Health under awards 1U19AG063744 and R01AG069901-01. ES is supported by NHLBI K23 HL151876. OA is supported by the NIH NIDDK K08 DK114558. FS was strongly supported by the Biomedical Research Program at Weill Cornell Medicine in Qatar, a program funded by the Qatar Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the institutional review board at Weill Cornell Medicine (protocol number 22-03024534). Written informed consent was received before participation by all patients, except when the institutional review board approved a waiver of informed consent (e.g., for the use of discarded samples and de-identified patient data).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at https://doi.org/10.6084/m9.figshare.20260998.v1